Wall Street analyst estimates for Seres Therapeutics, Inc. (MCRB): consensus price target, buy/hold/sell recommendations and forecasts for revenue, EPS and EBITDA for the upcoming fiscal years.
Seres Therapeutics, Inc. is a pioneering microbiome therapeutics firm dedicated to engineering bacterial consortia that modulate host cells and tissues to combat various diseases. Their flagship therapeutic, SER-109, an oral microbiome treatment, has successfully concluded Phase III clinical trials for the management of Clostridioides difficile infection (CDI).
Analyst Consensus
| Strong Buy | 0 |
| Buy | 11 |
| Hold | 3 |
| Sell | 4 |
| Strong Sell | 0 |
| Total analysts | 18 |
| Avg rating (1-5) | 0.39 |
Recent Earnings Surprises
| Date | EPS Actual | EPS Est. | vs Est. |
|---|---|---|---|
| 2026-11-04 | $-1.00 | ||
| 2026-08-05 | $0.47 | $-2.18 | +121.6% |
| 2026-05-05 | $-2.08 | $-1.88 | -10.6% |
| 2026-03-12 | $-1.78 | $-2.39 | +25.5% |
| 2025-11-05 | $0.94 | $0.05 | +1780.0% |
| 2025-08-06 | $-2.27 | $-2.72 | +16.5% |
| 2025-05-07 | $-3.75 | $-0.67 | -459.7% |
| 2025-03-13 | $-1.80 | $-0.17 | -958.8% |
Valuation Ratios
| Price / Book | 1.32 |
| EV / EBITDA | -2.17 |
| Dividend Yield | 0.00% |
Income Statement (10y)
| Year | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $21.8M | $32.1M | $28.3M | $34.5M | $33.2M | $144.9M | 0 | 0 | 0 | $789000 |
| Cost of Revenue | $82.0M | $89.5M | $96.0M | 0 | $90.6M | 0 | 0 | $19.3M | $3.5M | $4.1M |
| Gross Profit | -$60.2M | -$57.4M | -$67.7M | $34.5M | -$57.4M | $144.9M | 0 | -$19.3M | -$3.5M | -$3.3M |
| Research & Development | $82.0M | $89.5M | $96.0M | $80.1M | $90.6M | $141.9M | $109.7M | $117.6M | $64.6M | $49.1M |
| Selling, General & Admin | $32.6M | $34.0M | $32.6M | $24.7M | $30.8M | $69.3M | $70.3M | $77.5M | $53.2M | $39.2M |
| Operating Expenses | $114.6M | $123.5M | $128.6M | $106.4M | $30.8M | $209.4M | $179.9M | $175.8M | $117.8M | $90.6M |
| Operating Income | -$92.8M | -$91.4M | -$100.3M | -$71.9M | -$88.1M | -$64.5M | -$179.9M | -$195.1M | -$121.3M | -$94.0M |
| EBITDA | -$88.6M | -$82.1M | -$91.1M | -$62.2M | -$77.3M | -$56.7M | -$170.9M | -$181.4M | -$120.3M | $9.8M |
| Interest Expense | $969000 | $1.6M | $1.2M | $502000 | $2.9M | $2.9M | $6.0M | $13.2M | 0 | 0 |
| Pre-tax Income | -$91.6M | -$89.4M | -$98.9M | -$70.3M | -$89.1M | -$65.6M | -$183.6M | -$190.1M | -$125.8M | $5.7M |
| Income Tax | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Net Income | -$91.6M | -$89.4M | -$98.9M | -$70.3M | -$89.1M | -$65.6M | -$250.2M | -$113.7M | -$146.6M | $5.7M |
| EPS | $-46.00 | $-44.19 | $-48.57 | $-24.81 | $-22.34 | $-14.30 | $-46.29 | $-17.77 | $-18.86 | $0.64 |
| EPS (Diluted) | $-46.00 | $-44.19 | $-48.57 | $-24.81 | $-22.34 | $-14.30 | $-46.29 | $-17.77 | $-18.86 | $0.64 |
| Shares Outstanding (Diluted) | $2.0M | $2.0M | $2.0M | $2.8M | $4.0M | $4.6M | $5.4M | $6.4M | $7.8M | $8.9M |
Price
| Price | $4.21 |
| Market Cap | $41M |
| Exchange | NASDAQ |
| Country | US |
Related companies: ABOS · ACTU · APLT · CGTX · HURA · INO · IRD
Explore sector: Healthcare · Biotechnology
More sections of MCRB: Overview · Financials · Valuation · Statistics · Technical · Ownership · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks